NCT00521820 - Safety Comparison of Pioglitazone and Glyburide in Type 2 Diabetes Subjects With Mild to Moderate Congestive Heart Failure | Biotech Hunter

Enrollment

518

Participants

Timeline

Start Date

June 30, 2000

Primary Completion Date

October 31, 2003

Study Completion Date

October 31, 2003

Conditions

Diabetes Mellitus

Interventions

DRUG

Pioglitazone

Pioglitazone 30 mg (titrated to 45mg with tolerance), tablets, orally once daily and glyburide placebo-matching tablets, orally, once daily for up to 24 weeks.

DRUG

Glyburide

Pioglitazone placebo-matching tablets, orally, once daily and glyburide 10 mg (titrated to 15mg with tolerance), capsules, orally, once daily for up to 24 weeks.